SCOP Search:   
        by sunid, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Small proteins (3458)
(-)
Fold: Knottins (small inhibitors, toxins, lectins) (761)
(-)
Superfamily: EGF/Laminin (347)
(-)
Family: EGF-type module (304)
(-)
Protein domain: Activated protein c (autoprothrombin IIa) (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1AUTL:49-96; L:97-146HUMAN ACTIVATED PROTEIN C
(-)
Protein domain: automated matches (66)
(-)
Human (Homo sapiens) [TaxId: 9606] (66)
1W0YL:87-142TF7A_3771 COMPLEX
1W2KL:87-142TF7A_4380 COMPLEX
1W7XL:FACTOR7 - 413 COMPLEX
1W8BL:FACTOR7 - 413 COMPLEX
1Z6EL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389)
2AERL:87-142CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
2BMGA:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50
2BOKL:FACTOR XA - CATION
2BQ6A:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21
2BQ7A:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43
2BQWA:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
2BZ6L:ORALLY AVAILABLE FACTOR7A INHIBITOR
2EC9L:87-142CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
2FZZL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE
2G00L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL)BENZAMIDE
2JKHL:FACTOR XA - CATION INHIBITOR COMPLEX
2P16L:FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE
2P3TA:CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE
2P3UA:CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663}
2P93L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE
2P94L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE
2P95L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE
2Q1JB:THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS
2VVCK:; L:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVUL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVVL:AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
2VWLL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWMK:; L:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWNL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWOL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2W26B:FACTOR XA IN COMPLEX WITH BAY59-7939
2W3IB:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2
2W3KB:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1
2WPHE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT
2WPIE:FACTOR IXA SUPERACTIVE DOUBLE MUTANT
2WPJE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED
2WPKE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED
2WPLE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED
2WPME:FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED
2XBVL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBWL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBXL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBYL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC0L:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC4L:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC5L:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2Y5FL:FACTOR XA - CATION INHIBITOR COMPLEX
2Y5GL:FACTOR XA - CATION INHIBITOR COMPLEX
2Y5HL:FACTOR XA - CATION INHIBITOR COMPLEX
3CENL:FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2-PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE
3CS7L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)-6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3ENSA:90-126; A:127-178; C:89-126; C:127-178CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3-CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2-PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE
3FFGL:FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2'-((3-HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4, 5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3HPTA:90-126; A:127-178; C:89-126; C:127-178CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2-METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE
3K9XA:90-126; A:127-178; C:94-126; C:127-178X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
3KQBL:FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE
3KQCL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQDL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQEL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3M36L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[3-(AMINOMETHYL) PHENYL]-N-[3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC423)
3M37L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[2-(AMINOMETHYL) PHENYL]-N-(3-FLUORO-2'-SULFAMOYLBIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC602)
3SW2A:X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH 6-CHLORO-N-((3S)-2-OXO-1-(2-OXO-2-((5S)-8-OXO-5,6-DIHYDRO-1H-1,5-METHANOPYRIDO[1,2-A][1,5]DIAZOCIN-3(2H,4H,8H)-YL)ETHYL)PIPERIDIN-3-YL)NAPHTHALENE-2-SULFONAMIDE
3TH2L:87-142MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
3TH3L:87-142MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
3TH4L:87-142MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
4NGAL:FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-[2-(PROPAN-2-YLSULFONYL)BENZYL]ETHANAMIDE
(-)
Protein domain: Betacellulin-2 (2)
(-)
Human (Homo sapiens) [TaxId: 9606] (2)
1IOXA:NMR STRUCTURE OF HUMAN BETACELLULIN-2
1IP0A:NMR STRUCTURE OF HUMAN BETACELLULIN-2
(-)
Protein domain: Coagulation factor VIIa (45)
(-)
Human (Homo sapiens) [TaxId: 9606] (45)
1BF9A:N-TERMINAL EGF-LIKE DOMAIN FROM HUMAN FACTOR VII, NMR, 23 STRUCTURES
1CVWL:CRYSTAL STRUCTURE OF ACTIVE SITE-INHIBITED HUMAN COAGULATION FACTOR VIIA (DES-GLA)
1DANL:49-86; L:87-142COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR
1DVAL:42-86; L:87-142; M:42-86; M:87-142CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA
1F7EA:THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII, NMR, 20 STRUCTURES
1F7MA:THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII, NMR, MINIMIZED AVERAGE STRUCTURE
1FAKL:49-86; L:87-143HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
1FF7A:THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII (FUCOSYLATED AT SER-60), NMR, 20 STRUCTURES
1FFMA:THE FIRST EGF-LIKE DOMAIN FROM HUMAN BLOOD COAGULATION FVII (FUCOSYLATED AT SER-60), NMR, MINIMIZED AVERAGE STRUCTURE
1J9CL:48-86; L:87-142CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX
1JBUL:COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183
1KLIL:COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA
1KLJL:CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA
1O5DL:47-86; L:87-142DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1QFKL:49-86; L:87-144STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION
1WQVL:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE
1WSSL:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
1WTGL:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
1WUNL:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
1WV7L:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
1YGCL:SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR
1Z6JL:49-86; L:87-142CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
2A2QL:49-86; L:87-142COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+
2AEIL:49-86; L:87-142CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID
2B7DL:49-86; L:87-142FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL
2B8OL:49-86; L:87-142CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX
2C4FL:46-82; L:91-140CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121
2F9BL:49-86; L:87-142DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS
2FIRL:49-86; L:87-142CRYSTAL STRUCTURE OF DFPR-VIIA/STF
2FLBL:47-86; L:87-142DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR
2FLRL:47-86; L:87-142NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS
2PUQL:49-86; L:87-142CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
2ZP0L:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE
2ZWLL:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
2ZZUL:49-86; L:87-142HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
3ELAL:48-86; L:87-142CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR
4ISHL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR BMS-593214 ALSO KNOWN AS 2'-[(6R,6AR,11BR)-2-CARBAMIMIDOYL-6,6A,7,11B-TETRAHYDRO-5H-INDENO[2,1-C]QUINOLIN-6-YL]-5'-HYDROXY-4'-METHOXYBIPHENYL-4-CARBOXYLIC ACID
4ISIL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (6S)-N-(4-CARBAMIMIDOYLBENZYL)-1-CHLORO-3-(CYCLOBUTYLAMINO)-8,8-DIETHYL-4-OXO-4,6,7,8-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE
4JYUL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(PHENYLSULFONYL)ETHANAMIDE
4JYVL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-2-(ISOQUINOLIN-6-YLAMINO)-N-[(3-SULFAMOYLPHENYL)SULFONYL]ETHANAMIDE
4JZDL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(4-CARBAMIMIDOYLPHENYL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID
4JZEL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(1-AMINOISOQUINOLIN-6-YL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID
4JZFL:STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(3-CARBAMOYLPHENYL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID
4NA9L:FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 3'-AMINO-5'-[(2S,4R)-6-CARBAMIMIDOYL-4-PHENYL-1,2,3,4-TETRAHYDROQUINOLIN-2-YL]BIPHENYL-2-CARBOXYLIC ACID
4NG9L:FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(3-SULFAMOYLBENZYL)ETHANAMIDE
(-)
Protein domain: Complement C1S component (3)
(-)
Human (Homo sapiens) [TaxId: 9606] (3)
1NZIA:118-159; B:118-159CRYSTAL STRUCTURE OF THE CUB1-EGF INTERACTION DOMAIN OF COMPLEMENT PROTEASE C1S
4LMFA:117-159; B:117-159; C:117-159; D:117-159C1S CUB1-EGF-CUB2
4LORA:117-159C1S CUB1-EGF-CUB2 IN COMPLEX WITH A COLLAGEN-LIKE PEPTIDE FROM C1Q
(-)
Protein domain: Complement protease C1R (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1APQA:STRUCTURE OF THE EGF-LIKE MODULE OF HUMAN C1R, NMR, 19 STRUCTURES
(-)
Protein domain: E-selectin, EGF-domain (5)
(-)
Human (Homo sapiens) [TaxId: 9606] (5)
1ESLA:119-157INSIGHT INTO E-SELECTIN(SLASH)LIGAND INTERACTION FROM THE CRYSTAL STRUCTURE AND MUTAGENESIS OF THE LEC(SLASH)EGF DOMAINS
1G1QA:119-160; B:119-160; C:119-159; D:119-160CRYSTAL STRUCTURE OF P-SELECTIN LECTIN/EGF DOMAINS
1G1RA:119-160; C:119-159; D:119-160; B:119-160CRYSTAL STRUCTURE OF P-SELECTIN LECTIN/EGF DOMAINS COMPLEXED WITH SLEX
1G1SA:119-158; B:119-157P-SELECTIN LECTIN/EGF DOMAINS COMPLEXED WITH PSGL-1 PEPTIDE
1G1TA:119-157CRYSTAL STRUCTURE OF E-SELECTIN LECTIN/EGF DOMAINS COMPLEXED WITH SLEX
(-)
Protein domain: Epidermal growth factor, EGF (13)
(-)
Human (Homo sapiens) [TaxId: 9606] (5)
1IVOC:; D:CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN EPIDERMAL GROWTH FACTOR AND RECEPTOR EXTRACELLULAR DOMAINS.
1JL9A:; B:CRYSTAL STRUCTURE OF HUMAN EPIDERMAL GROWTH FACTOR
1NQLB:STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN EPIDERMAL GROWTH FACTOR (EGF) RECEPTOR IN AN INACTIVE (LOW PH) COMPLEX WITH EGF.
1P9JA:SOLUTION STRUCTURE AND DYNAMICS OF THE EGF/TGF-ALPHA CHIMERA T1E
2KV4A:EGF
(-)
Mouse (Mus musculus) [TaxId: 10090] (8)
1A3PA:ROLE OF THE 6-20 DISULFIDE BRIDGE IN THE STRUCTURE AND ACTIVITY OF EPIDERMAL GROWTH FACTOR, NMR, 20 STRUCTURES
1EGFA:SOLUTION STRUCTURE OF MURINE EPIDERMAL GROWTH FACTOR DETERMINED BY NMR SPECTROSCOPY AND REFINED BY ENERGY MINIMIZATION WITH RESTRAINTS
1EPGA:THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1EPHA:THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1EPIA:THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1EPJA:THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE STRUCTURES OF MOUSE EPIDERMAL GROWTH FACTOR IN ACIDIC AND PHYSIOLOGICAL PH SOLUTIONS
1GK5A:SOLUTION STRUCTURE THE MEGF/TGFALPHA44-50 CHIMERIC GROWTH FACTOR
3EGFA:SOLUTION STRUCTURE OF MURINE EPIDERMAL GROWTH FACTOR DETERMINED BY NMR SPECTROSCOPY AND REFINED BY ENERGY MINIMIZATION WITH RESTRAINTS
(-)
Protein domain: Epiregulin, EGF-domain (2)
(-)
Human (Homo sapiens) [TaxId: 9606] (2)
1K36A:NMR STRUCTURE OF HUMAN EPIREGULIN
1K37A:NMR STRUCTURE OF HUMAN EPIREGULIN
(-)
Protein domain: Factor IX (IXa) (8)
(-)
Human (Homo sapiens) [TaxId: 9606] (6)
1EDMB:; C:EPIDERMAL GROWTH FACTOR-LIKE DOMAIN FROM HUMAN FACTOR IX
1IXAA:THE THREE-DIMENSIONAL STRUCTURE OF THE FIRST EGF-LIKE MODULE OF HUMAN FACTOR IX: COMPARISON WITH EGF AND TGF-A
1RFNB:HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE
3KCGL:CRYSTAL STRUCTURE OF THE ANTITHROMBIN-FACTOR IXA-PENTASACCHARIDE COMPLEX
3LC3B:; D:BENZOTHIOPHENE INHIBITORS OF FACTOR IXA
3LC5B:SELECTIVE BENZOTHIOPHINE INHIBITORS OF FACTOR IXA
(-)
Pig (Sus scrofa) [TaxId: 9823] (2)
1PFXL:47-86; L:87-146PORCINE FACTOR IXA
1X7AL:50-86; L:87-146PORCINE FACTOR IXA COMPLEXED TO 1-{3-[AMINO(IMINO) METHYL]PHENYL}-N-[4-(1H-BENZIMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE
(-)
Protein domain: Factor X, N-terminal module (81)
(-)
Cow (Bos taurus) [TaxId: 9913] (5)
1APOA:THREE-DIMENSIONAL STRUCTURE OF THE APO FORM OF THE N-TERMINAL EGF-LIKE MODULE OF BLOOD COAGULATION FACTOR X AS DETERMINED BY NMR SPECTROSCOPY AND SIMULATED FOLDING
1CCFA:HOW AN EPIDERMAL GROWTH FACTOR (EGF)-LIKE DOMAIN BINDS CALCIUM-HIGH RESOLUTION NMR STRUCTURE OF THE CALCIUM FORM OF THE NH2-TERMINAL EGF-LIKE DOMAIN IN COAGULATION FACTOR X
1KIGL:BOVINE FACTOR XA
1WHEA:47-86COAGULATION FACTOR, NMR, 20 STRUCTURES
1WHFA:47-86COAGULATION FACTOR, NMR, 15 STRUCTURES
(-)
Human (Homo sapiens) [TaxId: 9606] (76)
1C5MF:STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1EZQB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515
1F0RB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815
1F0SB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208707
1FAXL:COAGULATION FACTOR XA INHIBITOR COMPLEX
1FJSL:CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA
1G2LB:FACTOR XA INHIBITOR COMPLEX
1G2MB:FACTOR XA INHIBITOR COMPLEX
1HCGB:STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION
1IOEL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55532
1IQEL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55590
1IQFL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55165
1IQGL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55159
1IQHL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55143
1IQIL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55125
1IQJL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55124
1IQKL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55113
1IQLL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54476
1IQML:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54471
1IQNL:HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55192
1KSNB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH FXV673
1LPGA:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
1LPKA:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
1LPZA:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1LQDA:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1MQ5L:CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL) AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1MQ6L:CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2-OXAZOLYL) METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1NFUB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747
1NFWB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685
1NFXB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944
1NFYB:CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095
1P0SL:87-138CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEX WITH ECOTIN M84R
1V3XB:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4-(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE
1WU1B:FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE
1XKAL:49-86; L:87-139FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XKBA:48-86; A:87-138; B:50-86; B:87-139FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
2BOHA:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND "1"
2CJIB:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2D1JB:FACTOR XA IN COMPLEX WITH THE INHIBITOR 2-[[4-[(5-CHLOROINDOL-2-YL)SULFONYL]PIPERAZIN-1-YL] CARBONYL]THIENO[3,2-B]PYRIDINE N-OXIDE
2EI6B:FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-CIS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2EI7B:FACTOR XA IN COMPLEX WITH THE INHIBITOR TRANS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2EI8B:FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-4-(N,N-DIMETHYLCARBAMOYL)-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL) CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2GD4A:87-138; L:87-138CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX
2H9EL:89-136CRYSTAL STRUCTURE OF FXA/SELECTIDE/NAPC2 TERNARY COMPLEX
2J2UB:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J34B:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J38B:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J4IB:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J94B:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J95B:CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2P3FL:CRYSTAL STRUCTURE OF THE FACTOR XA/NAP5 COMPLEX
2PHBB:AN ORALLY EFFICACIOUS FACTOR XA INHIBITOR
2PR3B:FACTOR XA INHIBITOR
2RA0L:X-RAY STRUCTURE OF FXA IN COMPLEX WITH 7-FLUOROINDAZOLE
2UWLB:SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWOB:SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWPB:FACTOR XA INHIBITOR COMPLEX
2VH0B:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS
2VH6B:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS
2WYGB:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS
2WYJB:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS
2Y7XB:THE DISCOVERY OF POTENT AND LONG-ACTING ORAL FACTOR XA INHIBITORS WITH TETRAHYDROISOQUINOLINE AND BENZAZEPINE P4 MOTIFS
2Y7ZB:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
2Y80B:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
2Y81B:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
2Y82B:STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
3IITB:FACTOR XA IN COMPLEX WITH A CIS-1,2-DIAMINOCYCLOHEXANE DERIVATIVE
3KL6B:DISCOVERY OF TETRAHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVE TAK-442: A POTENT, SELECTIVE AND ORALLY ACTIVE FACTOR XA INHIBITOR
3LIWB:FACTOR XA IN COMPLEX WITH (R)-2-(1-ADAMANTYLCARBAMOYLAMINO)-3-(3-CARBAMIDOYL-PHENYL)-N-PHENETHYL-PROPIONIC ACID AMIDE
3Q3KB:FACTOR XA IN COMPLEX WITH A PHENYLENEDIAMINE DERIVATIVE
3TK5B:FACTOR XA IN COMPLEX WITH D102-4380
3TK6B:FACTOR XA IN COMPLEX WITH D46-5241
4A7IA:FACTOR XA IN COMPLEX WITH A POTENT 2-AMINO-ETHANE SULFONAMIDE INHIBITOR
4BTIA:; E:FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 58.
4BTTA:; E:FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 31.
4BTUA:; E:FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 57.
(-)
Protein domain: Fibrillin-1 (7)
(-)
Human (Homo sapiens) [TaxId: 9606] (7)
1EMNA:2124-2166; A:2167-2205NMR STUDY OF A PAIR OF FIBRILLIN CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS, MINIMIZED AVERAGE STRUCTURE
1EMOA:2124-2166; A:2167-2205NMR STUDY OF A PAIR OF FIBRILLIN CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS, 22 STRUCTURES
1LMJA:3-46; A:47-88NMR STUDY OF THE FIBRILLIN-1 CBEGF12-13 PAIR OF CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS
1UZJA:1486-1528; A:1605-1647; B:2486-2528; B:2605-2647; C:3486-3528; C:3605-3647INTEGRIN BINDING CBEGF22-TB4-CBEGF33 FRAGMENT OF HUMAN FIBRILLIN-1, HOLO FORM.
1UZKA:1486-1528; A:1605-1647INTEGRIN BINDING CBEGF22-TB4-CBEGF33 FRAGMENT OF HUMAN FIBRILLIN-1, CA BOUND TO CBEGF23 DOMAIN ONLY
1UZPA:1486-1528; A:1605-1647INTEGRIN BINDING CBEGF22-TB4-CBEGF33 FRAGMENT OF HUMAN FIBRILLIN-1, SM BOUND FORM CBEGF23 DOMAIN ONLY.
1UZQA:1486-1528; A:1605-1647INTEGRIN BINDING CBEGF22-TB4-CBEGF33 FRAGMENT OF HUMAN FIBRILLIN-1, APO FORM CBEGF23 DOMAIN ONLY.
(-)
Protein domain: Heparin-binding epidermal growth factor, HBEGF (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1XDTR:COMPLEX OF DIPHTHERIA TOXIN AND HEPARIN-BINDING EPIDERMAL GROWTH FACTOR
(-)
Protein domain: Heregulin-alpha, EGF-like domain (4)
(-)
Human (Homo sapiens) [TaxId: 9606] (4)
1HAEA:HEREGULIN-ALPHA EPIDERMAL GROWTH FACTOR-LIKE DOMAIN, NMR, 20 STRUCTURES
1HAFA:HEREGULIN-ALPHA EPIDERMAL GROWTH FACTOR-LIKE DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
1HREA:SOLUTION STRUCTURE OF THE EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF HEREGULIN-ALPHA, A LIGAND FOR P180ERB4
1HRFA:SOLUTION STRUCTURE OF THE EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF HEREGULIN-ALPHA, A LIGAND FOR P180ERB4
(-)
Protein domain: Low density lipoprotein (LDL) receptor, different EGF domains (7)
(-)
Human (Homo sapiens) [TaxId: 9606] (7)
1HJ7A:293-333; A:334-372NMR STUDY OF A PAIR OF LDL RECEPTOR CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS, 20 STRUCTURES
1HZ8A:1-41; A:42-82SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A CONCATEMER OF EGF-HOMOLOGY MODULES OF THE HUMAN LOW DENSITY LIPOPROTEIN RECEPTOR
1I0UA:1-41; A:42-82SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A CONCATEMER OF EGF-HOMOLOGY MODULES OF THE HUMAN LOW DENSITY LIPOPROTEIN RECEPTOR
1IJQA:643-692; B:643-692CRYSTAL STRUCTURE OF THE LDL RECEPTOR YWTD-EGF DOMAIN PAIR
1N7DA:296-332; A:333-376; A:643-693EXTRACELLULAR DOMAIN OF THE LDL RECEPTOR
1XFEA:45-83SOLUTION STRUCTURE OF THE LA7-EGFA PAIR FROM THE LDL RECEPTOR
3BPSE:PCSK9:EGF-A COMPLEX
(-)
Protein domain: Mannose-binding protein associated serine protease 2, MASP2 (2)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1SZBA:124-168; B:124-168CRYSTAL STRUCTURE OF THE HUMAN MBL-ASSOCIATED PROTEIN 19 (MAP19)
(-)
Norway rat (Rattus norvegicus) [TaxId: 10116] (1)
1NT0A:120-164; G:120-164CRYSTAL STRUCTURE OF THE CUB1-EGF-CUB2 REGION OF MASP2
(-)
Protein domain: Neurogenic locus notch homolog protein 1, Notch1 (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1TOZA:411-452; A:453-491; A:492-526NMR STRUCTURE OF THE HUMAN NOTCH-1 LIGAND BINDING REGION
(-)
Protein domain: P-selectin, EGF-domain (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1FSBA:STRUCTURE OF THE EGF DOMAIN OF P-SELECTIN, NMR, 19 STRUCTURES
(-)
Protein domain: Plasminogen activator (tissue-type), t-PA (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1TPGA:51-91F1-G MODULE PAIR RESIDUES 1-91 (C83S) OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (T-PA) (NMR, 298K, PH2.95, REPRESENTATIVE STRUCTURE)
(-)
Protein domain: Plasminogen activator (urokinase-type) (6)
(-)
Human (Homo sapiens) [TaxId: 9606] (6)
1URKA:6-49SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2I9AA:10-49; B:6-49; C:11-49; D:10-49CRYSTAL STRUCTURE OF THE FREE AMINOTERMINAL FRAGMENT OF UROKINASE TYPE PLASMINOGEN ACTIVATOR (ATF)
2I9BA:11-49; B:11-49; C:11-49; D:11-49CRYSTAL STRUCTURE OF ATF-UROKINASE RECEPTOR COMPLEX
3BT1A:8-49STRUCTURE OF UROKINASE RECEPTOR, UROKINASE AND VITRONECTIN COMPLEX
3BT2A:9-49STRUCTURE OF UROKINASE RECEPTOR, UROKINASE AND VITRONECTIN COMPLEX
3U73A:10-49CRYSTAL STRUCTURE OF STABILIZED HUMAN UPAR MUTANT IN COMPLEX WITH ATF
(-)
Protein domain: Prostaglandin H2 synthase-1, EGF-like module (34)
(-)
Mouse (Mus musculus) [TaxId: 10090] (11)
1CVUA:33-73; B:2033-2073CRYSTAL STRUCTURE OF ARACHIDONIC ACID BOUND TO THE CYCLOOXYGENASE ACTIVE SITE OF COX-2
1CX2A:33-73; B:33-73; C:33-73; D:33-73CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A SELECTIVE INHIBITOR, SC-558
1DDXA:33-73; B:1033-1073; C:2033-2073; D:3033-3073CRYSTAL STRUCTURE OF A MIXTURE OF ARACHIDONIC ACID AND PROSTAGLANDIN BOUND TO THE CYCLOOXYGENASE ACTIVE SITE OF COX-2: PROSTAGLANDIN STRUCTURE
1PXXA:33-73; B:1033-1073; C:2033-2073; D:3033-3073CRYSTAL STRUCTURE OF DICLOFENAC BOUND TO THE CYCLOOXYGENASE ACTIVE SITE OF COX-2
3NTGA:18-58; B:18-58; C:18-58; D:18-58CRYSTAL STRUCTURE OF COX-2 WITH SELECTIVE COMPOUND 23D-(R)
3PGHA:33-73; B:33-73; C:33-73; D:33-73CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A NON-SELECTIVE INHIBITOR, FLURBIPROFEN
4COXA:33-73; B:33-73; C:33-73; D:33-73CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A NON-SELECTIVE INHIBITOR, INDOMETHACIN
4FM5A:32-72; B:32-72; C:32-72; D:32-72X-RAY STRUCTURE OF DES-METHYLFLURBIPROFEN BOUND TO MURINE COX-2
4M11A:33-73; B:33-73; C:33-73; D:33-73CRYSTAL STRUCTURE OF MURINE CYCLOOXYGENASE-2 COMPLEX WITH MELOXICAM
5COXA:33-73; B:33-73; C:33-73; D:33-73UNINHIBITED MOUSE CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2)
6COXA:33-73; B:33-73CYCLOOXYGENASE-2 (PROSTAGLANDIN SYNTHASE-2) COMPLEXED WITH A SELECTIVE INHIBITOR, SC-558 IN I222 SPACE GROUP
(-)
Sheep (Ovis aries) [TaxId: 9940] (23)
1CQEA:32-73; B:31-73PROSTAGLANDIN H2 SYNTHASE-1 COMPLEX WITH FLURBIPROFEN
1DIYA:32-73CRYSTAL STRUCTURE OF ARACHIDONIC ACID BOUND IN THE CYCLOOXYGENASE ACTIVE SITE OF PGHS-1
1EBVA:33-73OVINE PGHS-1 COMPLEXED WITH SALICYL HYDROXAMIC ACID
1EQGA:33-73; B:33-73THE 2.6 ANGSTROM MODEL OF OVINE COX-1 COMPLEXED WITH IBUPROFEN
1EQHA:33-73; B:33-73THE 2.7 ANGSTROM MODEL OF OVINE COX-1 COMPLEXED WITH FLURBIPROFEN
1FE2A:32-73CRYSTAL STRUCTURE OF DIHOMO-GAMMA-LINOLEIC ACID BOUND IN THE CYCLOOXYGENASE CHANNEL OF PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE-1.
1HT5A:33-73; B:33-73THE 2.75 ANGSTROM RESOLUTION MODEL OF OVINE COX-1 COMPLEXED WITH METHYL ESTER FLURBIPROFEN
1HT8A:33-73; B:33-73THE 2.7 ANGSTROM RESOLUTION MODEL OF OVINE COX-1 COMPLEXED WITH ALCLOFENAC
1IGXA:32-73CRYSTAL STRUCTURE OF EICOSAPENTANOIC ACID BOUND IN THE CYCLOOXYGENASE CHANNEL OF PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE-1.
1IGZA:32-73CRYSTAL STRUCTURE OF LINOLEIC ACID BOUND IN THE CYCLOOXYGENASE CHANNEL OF PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE-1.
1PGEA:33-73; B:33-73PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH P-(2'-IODO-5'-THENOYL) HYDROTROPIC ACID (IODOSUPROFEN)
1PGFA:33-73; B:33-73PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH 1-(4-IODOBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETIC ACID (IODOINDOMETHACIN), CIS MODEL
1PGGA:33-73; B:33-73PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH 1-(4-IODOBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETIC ACID (IODOINDOMETHACIN), TRANS MODEL
1PRHA:33-73; B:33-73THE X-RAY CRYSTAL STRUCTURE OF THE MEMBRANE PROTEIN PROSTAGLANDIN H2 SYNTHASE-1
1PTHA:33-73; B:33-73THE STRUCTURAL BASIS OF ASPIRIN ACTIVITY INFERRED FROM THE CRYSTAL STRUCTURE OF INACTIVATED PROSTAGLANDIN H2 SYNTHASE
1Q4GA:32-73; B:32-732.0 ANGSTROM CRYSTAL STRUCTURE OF OVINE PROSTAGLANDIN H2 SYNTHASE-1, IN COMPLEX WITH ALPHA-METHYL-4-BIPHENYLACETIC ACID
1U67A:32-73CRYSTAL STRUCTURE OF ARACHIDONIC ACID BOUND TO A MUTANT OF PROSTAGLADIN H SYNTHASE-1 THAT FORMS PREDOMINANTLY 11-HPETE.
2AYLA:32-73; B:1032-10732.0 ANGSTROM CRYSTAL STRUCTURE OF MANGANESE PROTOPORPHYRIN IX-RECONSTITUTED OVINE PROSTAGLANDIN H2 SYNTHASE-1 COMPLEXED WITH FLURBIPROFEN
3KK6A:32-73; B:32-73CRYSTAL STRUCTURE OF CYCLOOXYGENASE-1 IN COMPLEX WITH CELECOXIB
3N8WA:32-73CRYSTAL STRUCTURE OF R120Q/NATIVE CYCLOOXYGENASE-1 HETERODIMER MUTANT IN COMPLEX WITH FLURBIPROFEN
3N8XA:32-73; B:32-73CRYSTAL STRUCTURE OF CYCLOOXYGENASE-1 IN COMPLEX WITH NIMESULIDE
3N8YA:32-73; B:32-73STRUCTURE OF ASPIRIN ACETYLATED CYCLOOXYGENASE-1 IN COMPLEX WITH DICLOFENAC
3N8ZA:32-73; B:32-73CRYSTAL STRUCTURE OF CYCLOOXYGENASE-1 IN COMPLEX WITH FLURBIPROFEN
(-)
Protein domain: Thrombomodulin, different EGF-like domains (6)
(-)
Human (Homo sapiens) [TaxId: 9606] (6)
1ADXA:FIFTH EGF-LIKE DOMAIN OF THROMBOMODULIN (TMEGF5), NMR, 14 STRUCTURES
1DQBA:1-44; A:45-83NMR STRUCTURE OF THROMBOMODULIN EGF(4-5)
1DX5I:345-387; I:388-422; L:388-422; L:423-462; I:423-462; J:345-387; J:388-422; J:423-462; K:345-387; K:388-422; K:423-462; L:345-387CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
1TMRA:THE STRUCTURE OF A 19 RESIDUE FRAGMENT FROM THE C-LOOP OF THE FOURTH EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF THROMBOMODULIN
1ZAQA:FOURTH EGF-LIKE DOMAIN OF THROMBOMODULIN, NMR, 12 STRUCTURES
2ADXA:FIFTH EGF-LIKE DOMAIN OF THROMBOMODULIN (TMEGF5), NMR, MINIMIZED AVERAGE STRUCTURE
(-)
Protein domain: Transforming growth factor alpha (7)
(-)
Human (Homo sapiens) [TaxId: 9606] (7)
1MOXC:; D:CRYSTAL STRUCTURE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (RESIDUES 1-501) IN COMPLEX WITH TGF-ALPHA
1YUFA:TYPE ALPHA TRANSFORMING GROWTH FACTOR, NMR, 16 MODELS WITHOUT ENERGY MINIMIZATION
1YUGA:TYPE ALPHA TRANSFORMING GROWTH FACTOR, NMR, 15 MODELS AFTER ECEPP/3 ENERGY MINIMIZATION
2TGFA:THE SOLUTION STRUCTURE OF HUMAN TRANSFORMING GROWTH FACTOR ALPHA
3E50D:CRYSTAL STRUCTURE OF HUMAN INSULIN DEGRADING ENZYME IN COMPLEX WITH TRANSFORMING GROWTH FACTOR-ALPHA
3TGFA:THE SOLUTION STRUCTURE OF HUMAN TRANSFORMING GROWTH FACTOR ALPHA
4TGFA:SOLUTION STRUCTURES OF HUMAN TRANSFORMING GROWTH FACTOR ALPHA DERIVED FROM 1*H NMR DATA